Overcoming brain-derived therapeutic resistance in HER2+ breast cancer brain metastasis
D. Ippolitov, Y.-H. Lin, J. Spence, A. Glogowska, T. Thanasupawat, J. Beiko, M. R. Del Bigio, X. Xu, A. Wang, R. Calvo, A. Kapoor, J. J. Marugan, M. J. Henderson, T. Klonisch, S. Hombach-Klonisch
This study establishes a patient-derived HER2+ brain metastasis model and identifies Poziotinib as an effective RTKi for treating HER2+ breast cancer brain metastasis in mice.
bioRxiv · Feb 19, 2024 · PreprintCancer Biology